{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:27:40Z","timestamp":1794414460519,"version":"4.9.1"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2026,11,1]]},"abstract":"\n Importance<\/jats:title>\n Among patients with heart failure (HF) in contemporary US clinical practice, the burden of overlapping cardiovascular-kidney-metabolic (CKM) conditions and the associated impact on outcomes remain poorly characterized.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the prevalence of CKM multimorbidity and the impact on clinical outcomes in patients hospitalized for HF across the spectrum of ejection fraction (EF).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This was a retrospective cohort study of patients hospitalized for HF at US hospitals participating in the Get With The Guidelines\u2013Heart Failure (GWTG-HF) registry. The analysis included patients hospitalized for HF in the GWTG-HF registry between 2019-2025 and Medicare beneficiaries hospitalized for HF in the GWTG-HF registry between 2019-2023.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Presence of up to 4 additional CKM conditions including atherosclerotic cardiovascular disease, chronic kidney disease, diabetes, and obesity (body mass index \u226530; calculated as weight in kilograms divided by height in meters squared).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n In-hospital mortality, 1-year postdischarge all-cause mortality, and 1-year postdischarge HF readmission.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n This study included 725 205 patients (median [IQR] age, 72.0 [61.0-82.0] years; 386\u202f886 male [53.3%]) hospitalized for HF between 2019 and 2025 and 123 271 Medicare beneficiaries (median [IQR] age, 80 [73-87] years; 64\u202f375 female [52.2%]) hospitalized for HF between 2019 and 2023. Among 725\u202f205 patients hospitalized for HF, 521\u202f739 (71.9%) had 2 or more overlapping CKM conditions, and a minority of patients (48\u202f732 [6.7%]) had HF only. CKM overlap was greatest in HF with preserved EF (HFpEF). Compared with HF only, increasing number of overlapping CKM conditions was associated with stepwise increases in in-hospital mortality (4 CKM conditions: HF with reduced EF [HFrEF] adjusted odds ratio [aOR], 5.08; 95% CI, 4.43-5.83; HF with mildly reduced EF [HFmrEF] aOR, 2.37; 95% CI, 1.68-3.34; HFpEF aOR, 2.05; 95% CI, 1.77-2.38), and this association was strongest in HFrEF (\n P<\/jats:italic>\n for interaction &amp;lt;.001). Among Medicare beneficiaries hospitalized for HF, compared with HF only, increasing CKM multimorbidity was associated with increasing risks of postdischarge all-cause mortality (4 CKM conditions: HFrEF adjusted hazards ratio [aHR], 2.10; 95% CI, 1.93-2.29; HFmrEF aHR, 1.38; 95% CI, 1.17-1.63; HFpEF aHR, 1.09; 95% CI, 1.03-1.17) and HF readmission (4 CKM conditions: HFrEF aHR, 2.33; 95% CI, 2.12-2.56; HFmrEF aHR, 2.20; 95% CI, 1.82-2.66; HFpEF aHR, 1.91; 95% CI, 1.77-2.06), with steepest increases in risk among patients with HFrEF (\n P<\/jats:italic>\n for interaction &amp;lt;.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this contemporary cohort of US patients hospitalized for HF, most patients had multiple additional overlapping CKM conditions. Increasing CKM multimorbidity was independently associated with stepwise increases in mortality and readmission risk. Although these associations spanned the EF spectrum, the prognostic impact of CKM multimorbidity was greatest in HFrEF and least in HFpEF.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamacardio.2026.4215","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:31:39Z","timestamp":1790782299000},"page":"1040","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular-Kidney-Metabolic Overlap in Patients Hospitalized for Heart Failure"],"prefix":"10.1001","volume":"11","author":[{"given":"Veraprapas","family":"Kittipibul","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina"},{"name":"Duke Clinical Research Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iyanuoluwa","family":"Ayodele","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California"},{"name":"Associate Editor, JAMA Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Alhanti","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriette G. C.","family":"Van Spall","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada"},{"name":"Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambarish","family":"Pandey","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabra C.","family":"Lewsey","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Greene","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina"},{"name":"Duke Clinical Research Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"20","key":"hoi260054r1","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association.","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"15","key":"hoi260054r2","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease.","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"hoi260054r3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes.","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"hoi260054r4","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jchf.2023.05.015","article-title":"Cardio-renal-metabolic overlap, outcomes, and dapagliflozin in heart failure with mildly reduced or preserved ejection fraction.","volume":"11","author":"Ostrominski","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"6","key":"hoi260054r5","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"16","key":"hoi260054r6","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction.","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"hoi260054r7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomized controlled trials.","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"hoi260054r8","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1161\/CIRCULATIONAHA.120.047019","article-title":"Temporal trends in prevalence and prognostic implications of comorbidities among patients with acute decompensated heart failure: the ARIC study community surveillance.","volume":"142","author":"Pandey","year":"2020","journal-title":"Circulation"},{"issue":"8","key":"hoi260054r9","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1002\/ejhf.3304","article-title":"Cardiovascular-kidney-metabolic overlap in heart failure with preserved ejection fraction: cardiac structure and function, clinical outcomes, and response to sacubitril\/valsartan in PARAGON-HF.","volume":"26","author":"Lassen","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"hoi260054r10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jacc.2024.05.005","article-title":"Cardiovascular-kidney-metabolic overlap in heart failure with mildly reduced or preserved ejection fraction: a trial-level analysis.","volume":"84","author":"Ostrominski","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"hoi260054r11","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1016\/j.ahj.2004.09.015","article-title":"The American Heart Association Get With The Guidelines program.","volume":"148","author":"Smaha","year":"2004","journal-title":"Am Heart J"},{"issue":"6","key":"hoi260054r12","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.ahj.2009.04.002","article-title":"Linking inpatient clinical registry data to Medicare claims data using indirect identifiers.","volume":"157","author":"Hammill","year":"2009","journal-title":"Am Heart J"},{"issue":"7","key":"hoi260054r13","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/jamacardio.2021.0611","article-title":"Association of dual eligibility for Medicare and Medicaid with heart failure quality and outcomes among Get With The Guidelines\u2013Heart Failure hospitals.","volume":"6","author":"Bahiru","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"18","key":"hoi260054r14","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1136\/heartjnl-2025-327053","article-title":"Burden of chronic kidney disease and outcomes following hospitalization for heart failure.","volume":"112","author":"Averbuch","year":"2026","journal-title":"Heart"},{"issue":"4","key":"hoi260054r15","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jchf.2025.01.014","article-title":"Overcoming the risk-treatment paradox: prescribing GDMT for severe heart failure.","volume":"13","author":"Greene","year":"2025","journal-title":"JACC Heart Fail"},{"issue":"25","key":"hoi260054r16","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1016\/j.jacc.2023.04.034","article-title":"Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations.","volume":"81","author":"Usman","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"hoi260054r17","article-title":"Sodium-glucose cotransporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.","volume":"5","author":"Natale","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"issue":"16","key":"hoi260054r18","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.jacc.2025.06.055","article-title":"The adipokine hypothesis of heart failure with a preserved ejection fraction: a novel framework to explain pathogenesis and guide treatment.","volume":"86","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"hoi260054r19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ijcard.2020.04.068","article-title":"Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: a blueprint for clinical trial design.","volume":"313","author":"Savarese","year":"2020","journal-title":"Int J Cardiol"},{"issue":"16","key":"hoi260054r20","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1161\/CIRCULATIONAHA.123.068524","article-title":"Accelerated risk-based implementation of guideline-directed medical therapy for type 2 diabetes and chronic kidney disease.","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"issue":"7","key":"hoi260054r21","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jamacardio.2021.0496","article-title":"Simultaneous or rapid sequence initiation of quadruple medical therapy for heart failure-optimizing therapy with the need for speed.","volume":"6","author":"Greene","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"5","key":"hoi260054r22","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1001\/jamacardio.2025.0038","article-title":"Simultaneous or rapid initiation of combination therapy for heart failure with preserved ejection fraction.","volume":"10","author":"Greene","year":"2025","journal-title":"JAMA Cardiol"},{"issue":"4","key":"hoi260054r23","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1161\/CIRCOUTCOMES.108.822692","article-title":"Representativeness of a national heart failure quality-of-care registry: comparison of OPTIMIZE-HF and non-OPTIMIZE-HF Medicare patients.","volume":"2","author":"Curtis","year":"2009","journal-title":"Circ Cardiovasc Qual Outcomes"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2854822\/jamacardiology_kittipibul_2026_oi_260054_1793998744.78343.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:01:29Z","timestamp":1794412889000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2854822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11,1]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2026.4215","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11,1]]}}}